Patients with metastatic NSCLC, targetable driver oncogene molecular variant, and also PD-L1 expression levels of 1% or more should receive first-line targeted therapy for detected oncogene instead of first-line immune checkpoint inhibitors (ICIs). Here, CD274 is linked to non-small cell lung carcinoma.